IASO-782 / IASO BIO - LARVOL DELTA

IASO-782 in Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Shanghai IASO Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

IASO-782 in Autoimmune Hematological Diseases (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Shanghai IASO Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2025 ➔ Dec 2027 | Trial primary completion date: Nov 2025 ➔ Oct 2027

Enrollment open • Trial completion date • Trial primary completion date • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

IASO-782 in Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Shanghai IASO Biotechnology Co., Ltd

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication -- Systemic Lupus Erythematosus (SLE) (PRNewswire) - "IASO Biotechnology...hereby announces that the investigational new drug (IND) application for IASO-782 Injection...has been approved by the National Medical Products Administration (NMPA) for the treatment of a new indication — systemic lupus erythematosus (SLE)."

New trial • Systemic Lupus Erythematosus

IASO-782 in Autoimmune Hematological Diseases (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Shanghai IASO Biotechnology Co., Ltd

New P1 trial • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology • Thrombocytopenia • Thrombocytopenic Purpura